In a Q&A with Stat’s Ed Silverman, CEO Henry Skinner expressed concerns over the lack of innovation in the antimicrobial pipeline, discussed the lack of private investment in the space, and explained the need for policy reforms in the U.S. and globally.
"What we need is a way to get policymakers to address market failure, but there’s been limited progress. But we also need to recognize that the majority of innovation across the health care continuum doesn’t happen in big companies. It happens in smaller companies that get acquired by large companies with the know-how and capital to move something forward," Skinner said. "So the criticism that the Pasteur Act was a handout to big companies was a little bit unfair, because that’s not where the risk taking is located."
Read the full Q&A here.
